Why the Mesoblast (ASX:MSB) share price is up 6%

The Mesoblast Limited (ASX: MSB) share price is up more than 6% after announcing that it has won an award.

Mesoblast describes itself as a global leader in allogeneic cellular medicines for inflammatory diseases.

Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.

With the extensive imflammatory response in COVID-19 infections, remestemcel-L is also being evaluated in a randomized, controlled phase 3 trial in up to 300 ventilator-dependent adults with moderate to severe acute respiratory distress syndrome, which is the primary cause of mortality in COVID-19 patients. Mesoblast recently announced that the independent Data Safety Monitoring Board (DSMB) recommended continuation of the phase 3 trial.

Mesoblast’s award win

Mesoblast announced that its lead product candidate remestemcel-L has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 for Biotech Innovation.

About the the award

The awards highlight companies that demonstrate innovative solutions, technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

The evaluation criteria are: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.

The awards program’s applications were reviewed by a panel of executives from major biotech and pharma companies including Astellas, Accenture, AstraZeneca, Angiocrine Bioscience, Biotech Research Group, NIHR Clinical Research Network, Medidata Solutions and PPD.

Mesoblast management comments

Mesoblast CEO Dr Silviu Itescu said: “This important award is recognition of Mesoblast’s leadership as an innovator in the cell therapy industry, and of the potential for remestemcel-L to profoundly impact the lives of children suffering with steroid-refractory acute graft versus host disease.”

Summary

The biotech business reminded investors that remestemcel-L remains under priority review by the US FDA. If approved, the product launch is expected in 2020. The FDA has set a Prescription Drug User Fee Act action date of 30 September 2020.

Mesoblast is a very interesting investment idea. It seems like the type of investment outcome where either its products will be approved and shares go up, or it’s not approved and shares go down.

It seems more likely to be approved than not, so it could do very well over the rest of the year, but that’s not how I like to invest. I prefer ASX growth shares with more predictable outcomes like Pushpay Holdings Ltd (ASX: PPH).

Expert Analyst Report: 1 ASX Stock for 2020 & Beyond

Want to know the name of 1 of our lead analyst’s top 10 growth stocks?

Enter your email below to receive a 3,500-word analyst report, valuation research note, exclusive CEO interview and more.

It’s completely free. Just enter your email and we’ll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Expert Analyst Report: 1 ASX Stock for 2020 & Beyond

Want to know the name of 1 of our lead analyst’s top 10 growth stocks?

Click here to access our free member content, including this 3,500-word analyst report, valuation research note, exclusive CEO interview and more. It’s completely free.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading: